Brian Mueller Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Brian Mueller is EVP, Chief Financial Officer of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 71,571 shares of BMRN, which is worth approximately $4.6 Million. The most recent transaction as insider was on Jun 28, 2024, when has been sold 588 shares (Common Stock) at a price of $82.33 per share, resulting in proceeds of $48,410. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 71.6K

0% 3M change

56.25% 12M change

Total Value Held $4.6 Million

Brian Mueller Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 28 2024	SELL Payment of exercise price or tax liability	$48,410 $82.33 p/Share	588 Reduced 0.81%	71,571 Common Stock
May 30 2024	SELL Open market or private sale	$375,950 $75.19 p/Share	5,000 Reduced 6.48%	72,159 Common Stock
May 30 2024	BUY Exercise of conversion of derivative security	$315,500 $63.1 p/Share	5,000 Added 6.09%	77,159 Common Stock
Apr 30 2024	BUY Grant, award, or other acquisition	$20,595 $68.65 p/Share	300 Added 0.41%	72,159 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$1,743,573 $83.87 p/Share	20,789 Reduced 22.44%	71,859 Common Stock
Mar 15 2024	BUY Grant, award, or other acquisition	-	11,400 Added 10.96%	92,648 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	35,125 Added 30.18%	81,248 Common Stock
Jun 29 2023	SELL Payment of exercise price or tax liability	$869,735 $88.93 p/Share	9,780 Reduced 17.59%	45,805 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$371,117 $93.41 p/Share	3,973 Reduced 6.67%	55,585 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$237,599 $87.74 p/Share	2,708 Reduced 4.35%	59,558 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	9,630 Added 13.39%	62,266 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	24,890 Added 32.11%	52,636 Common Stock
Jan 13 2023	SELL Open market or private sale	$286,250 $114.5 p/Share	2,500 Reduced 8.27%	27,746 Common Stock
Jan 13 2023	BUY Exercise of conversion of derivative security	$157,750 $63.1 p/Share	2,500 Added 7.63%	30,246 Common Stock
Dec 13 2022	SELL Open market or private sale	$268,750 $107.5 p/Share	2,500 Reduced 8.27%	27,746 Common Stock
Dec 13 2022	BUY Exercise of conversion of derivative security	$157,750 $63.1 p/Share	2,500 Added 7.63%	30,246 Common Stock
Dec 02 2022	SELL Open market or private sale	$731,604 $104.5 p/Share	7,001 Reduced 20.15%	27,746 Common Stock
Dec 02 2022	BUY Exercise of conversion of derivative security	$400,079 $67.81 p/Share	5,900 Added 15.77%	31,507 Common Stock
Nov 23 2022	SELL Open market or private sale	$527,303 $98.03 p/Share	5,379 Reduced 15.72%	28,847 Common Stock
Nov 23 2022	BUY Exercise of conversion of derivative security	$237,335 $67.81 p/Share	3,500 Added 9.76%	32,347 Common Stock
Aug 05 2022	SELL Open market or private sale	$330,750 $94.5 p/Share	3,500 Reduced 10.23%	30,726 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	$237,335 $67.81 p/Share	3,500 Added 9.28%	34,226 Common Stock
Jul 08 2022	SELL Open market or private sale	$656,662 $89.5 p/Share	7,337 Reduced 19.28%	30,726 Common Stock
Jun 29 2022	SELL Payment of exercise price or tax liability	$48,338 $83.92 p/Share	576 Reduced 1.49%	38,063 Common Stock
May 04 2022	SELL Open market or private sale	$997,100 $84.5 p/Share	11,800 Reduced 23.39%	38,639 Common Stock

Brian Mueller

EVP, Chief Financial Officer

Novato, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMRN shares.

Notify only if

Value

Insider Trading

Get notified when an Biomarin Pharmaceutical Inc insider buys or sells BMRN shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOMARIN PHARMACEUTICAL INC

Track Activities on BMRN

Account